MediWound Starts Testing MW005 In Two Mid-Stage Trials In Patients With Non-Melanoma Skin Cancer
- MediWound Ltd (NASDAQ: MDWD) has initiated a Phase 1/2 study of MW005 to treat low-risk Basal Cell Carcinoma (BCC).
- In parallel, an investigator-initiated Phase 2 trial of MW005 in non-melanoma skin cancers is being conducted at the Soroka Medical Center in Israel.
- MediWound expects that data from both studies will be available by the end of 2021.
- The 32-subject study is designed to evaluate the safety and tolerability of MW005 in BCC using different schedules of administration, as well as to provide a preliminary evaluation of its efficacy, as measured by the percentage of target lesions with complete histological clearance.
- The investigator-initiated trial will evaluate the safety and efficacy of MW005 in removing non-melanoma skin cancers and pre-cancerous lesions in up to 50 patients.
- Price Action: MDWD shares traded higher by 0.77% at $3.93 on the last check Monday.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In: Briefs Phase 2 Trial Skin CancerBiotech News Penny Stocks Health Care General
